Natural Killer Cell (CYNK-001) Infusions in Adults with AML

ClinicalTrials.gov ID: NCT04310592

Public ClinicalTrials.gov record NCT04310592. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 26, 2026, 3:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) with or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) or Relapsed/refractory (R/R) AML

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating acute myeloid leukemia.

Study identification

NCT ID: NCT04310592
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Celularity Incorporated; Industry
Enrollment: 27 participants

Eligibility (public fields only)

Age range: 18 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 12, 2020 (Actual)
Primary completion: Jan 20, 2023 (Actual)
Completion: Apr 28, 2023 (Actual)
Last update posted: Dec 12, 2024

2020 – 2023

United States locations

U.S. sites: 10
U.S. states: 7
U.S. cities: 9

Facility	City	State	ZIP	Site status
Colorado Blood Cancer Institute	Denver	Colorado	80218	—
University of Chicago	Chicago	Illinois	60637	—
Hackensack University Medical Center	Hackensack	New Jersey	07601	—
Roswell Park Comprehensive Cancer Center	Buffalo	New York	14203	—
Columbia University and New York Presbyterian Hospital	New York	New York	10032	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Westchester Medical Center	Valhalla	New York	10595	—
Tennessee Oncology	Nashville	Tennessee	37203	—
MD Anderson Cancer Center	Houston	Texas	77030	—
Swedish Health Services	Seattle	Washington	98122	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04310592, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 12, 2024 · Synced Oct 26, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04310592 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →